• 1. Iron-catalyzed oxidative functionalization of C(sp3)–H bonds under bromide-synergized mild conditions
  Han Yu,Qixin Zhao,Zheyu Wei,Zhikang Wu,Qi Li,Sheng Han,Yongge Wei Chem. Commun. 2019 55 7840
• 2. Copper-catalysed oxidative Csp3–H methylenation to terminal olefins using DMF
  Jianming Liu,Hong Yi,Xin Zhang,Chao Liu,Ren Liu,Guoting Zhang,Aiwen Lei Chem. Commun. 2014 50 7636
• 3. An efficient and metal free synthesis of benzylpyridines using HI through the deoxygenation reaction
  Selvaraj Chandrasekar,Iyyanar Karthikeyan,Govindasamy Sekar RSC Adv. 2015 5 58790
• 4. Visible-light-induced 4CzIPN/LiBr system: a tireless electron shuttle to enable reductive deoxygenation of N-heteroaryl carbonyls
  Shuai Zhong,Guo-Jun Deng,Zhiqi Dai,Huawen Huang Org. Chem. Front. 2021 8 4419
• 5. 445. Aminoalkyl tertiary carbinols and derived products. Part V. Antihistamines. The stereochemistry of cis- and trans-3-phenyl-3-pyridylallylamines
  D. W. Adamson,P. A. Barrett,J. W. Billinghurst,T. S. G. Jones J. Chem. Soc. 1957 2315

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Chlorobenzenes
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Halobenzenes Chlorobenzenes

Introduction to 2-[(4-chlorophenyl)methyl]pyridine (CAS No. 4350-41-8)

2-[(4-chlorophenyl)methyl]pyridine, identified by the Chemical Abstracts Service Number (CAS No.) 4350-41-8, is a significant compound in the field of pharmaceutical chemistry and medicinal research. This heterocyclic organic molecule features a pyridine core substituted with a 4-chlorophenylmethyl group, making it a versatile intermediate in the synthesis of various biologically active agents. The structural configuration of this compound imparts unique chemical properties that make it valuable in drug discovery and development pipelines.

The pyridine moiety is a cornerstone in medicinal chemistry due to its prevalence in numerous pharmacologically active compounds. Its nitrogen atom allows for hydrogen bonding interactions, enhancing binding affinity to biological targets. In contrast, the 4-chlorophenylmethyl side chain introduces lipophilicity and electronic modulation, which are critical for optimizing pharmacokinetic profiles. This combination of features has positioned 2-[(4-chlorophenyl)methyl]pyridine as a building block for designing novel therapeutic agents.

Recent advancements in computational chemistry and high-throughput screening have highlighted the potential of 2-[(4-chlorophenyl)methyl]pyridine in addressing complex diseases. Studies indicate that derivatives of this compound exhibit promising activity against enzymes involved in inflammatory pathways. For instance, modifications to the 4-chlorophenylmethyl group have been explored to enhance selectivity and reduce off-target effects, aligning with the growing demand for precision medicine.

In the realm of oncology research, 2-[(4-chlorophenyl)methyl]pyridine has been investigated as a scaffold for kinase inhibitors. The pyridine ring serves as a key interaction site with ATP-binding pockets of target kinases, while the chloro-substituent on the phenyl ring enhances binding affinity through electrostatic interactions. Preliminary studies have demonstrated that certain analogs derived from this compound exhibit inhibitory effects on mutant forms of kinases implicated in cancer progression.

The synthesis of 2-[(4-chlorophenyl)methyl]pyridine typically involves palladium-catalyzed cross-coupling reactions between 4-bromopyridine and chlorobenzylmagnesium bromide, followed by purification via column chromatography. Alternatively, nucleophilic aromatic substitution reactions can be employed to introduce the chloro-substituent at the desired position. These synthetic routes underscore the compound's accessibility and scalability for industrial applications.

From a pharmacokinetic perspective, the metabolic stability of 2-[(4-chlorophenyl)methyl]pyridine derivatives is a critical consideration. Xenobiotic metabolism studies suggest that the pyridine ring undergoes oxidative degradation via cytochrome P450 enzymes, while the aromatic side chain may be susceptible to aromatic hydroxylation. Understanding these metabolic pathways is essential for designing prodrugs or analogs with improved bioavailability and reduced clearance rates.

The role of 2-[(4-chlorophenyl)methyl]pyridine in central nervous system (CNS) drug development is also noteworthy. The lipophilic nature of its structure facilitates blood-brain barrier penetration, making it a candidate for treating neurodegenerative disorders. Recent preclinical trials have explored its derivatives as potential modulators of neurotransmitter receptors, including serotonin and dopamine pathways, which are implicated in conditions such as Alzheimer's disease and Parkinson's disease.

Environmental considerations regarding 2-[(4-chlorophenyl)methyl]pyridine warrant attention as well. While not classified as hazardous under current regulatory frameworks, its persistence in aquatic environments could pose ecological risks if improper disposal practices are employed. Researchers are investigating green chemistry alternatives to minimize waste generation during synthesis and explore biodegradable derivatives that decompose into non-toxic byproducts.

In conclusion, 2-[(4-chlorophenyl)methyl]pyridine (CAS No. 4350-41-8) represents a valuable asset in modern drug discovery programs due to its structural versatility and functional adaptability. Ongoing research continues to uncover new therapeutic applications for this compound and its derivatives across multiple disease domains. As scientific understanding evolves, so too will the synthetic methodologies and applications that leverage its unique chemical properties.

• 227803-33-0(1H-Indole,5-chloro-2-(phenylmethyl)-)
• 101200-53-7(Pyridine,2-[3-(3-chlorophenyl)propyl]-)
• 6320-64-5(Pyridine,2-[(4-chlorophenyl)methyl]-, hydrochloride (1:1))
• 1159815-12-9(5-Chloro-2-ethylpyridine)
• 106129-20-8(Isoquinoline, 1-[(3-chlorophenyl)methyl]-)
• 101-82-6(2-Benzylpyridine)
• 94022-31-8(Pyridine,2-[3-(4-chlorophenyl)propyl]-)
• 126309-07-7(pyridine, 2-benzyl-, hydrochloride)
• 106129-19-5(Isoquinoline, 1-[(2-chlorophenyl)methyl]-)
• 137018-26-9(2,2'-[(4-chlorophenyl)methylene]bis-1H-Pyrrole)